INTERPHEX Innovations - Pharmaceutical Technology

Latest Issue

Latest Issue
PharmTech Europe

INTERPHEX Innovations
Visitors found new container options, child-resistant concepts, and serialization solutions. This article contains bonus online material.

Pharmaceutical Technology
Volume 35, Issue 5, pp. 38-43

Single-use systems

Because of growing interest, several exhibitors showcased single-use systems. A 50-cm3 peristaltic pump for single-use dosing systems has joined a 6-cm3 option. Tubing can be removed and replaced with one hand. Offset rollers minimize pulsation and improve fill accuracy to 0.5 mL (PreVAS Single-use Dosing System, Bosch Packaging Technology).

At least four other firms offer peristaltic pumps for single-use systems (Bausch and Stroebel, Watson-Marlow, Flexicon Liquid Filling, and Colanar). But, peristaltic pumps are not the only style available for single-use systems. A single-use rolling-diaphragm pump built of polycarbonate with a platinum-cured silicone diaphragm is assembled in a cleanroom, 100% integrity tested, and delivered with custom tubing sets. The prevalidated, presterilized, and preassembled system offers accuracy of 10 mg on fills equal to or less than 2 mL and 0.5% on fills greater than 2 mL (PreVAS Dosing System).

A disposable turning valve pump also is supplied as part of a preassembled, presterilized system, which includes tubing and filling needles. Targeted for vials, eye-drop bottles, syringes, and cartridges, it offers high accuracy on fills from 0.1 to 3 mL and handles virtually any liquid, including highly viscous or shear-sensitive ones (Disposable Filling System, Groninger).

New inkjet coders

For coding needs, a 35 character/s continuous inkjet (CIJ) printer is reportedly 20% faster than competing systems. The IP65-rated unit is washdown compatible and recirculates solvent so that it consumes only 2 mL/h, compared with 4–7 mL for other systems. With only six moving parts and a simplified ink system, maintenance requirements are minimal. The printer also features a removable operator interface and uses volatile organic compound-free inks (alphaJET evo continuous inkjet printer, Oncode).

Another CIJ printer needs no preventative maintenance at all—just routine replacement of consumables, which are color-coded for easy identification. A modular design eliminates the traditional ink reservoir and separates ink and filters from pump and associated electronics so that ink disposal doesn't scrap viable mechanical and electrical components. Other features include a simplified operator interface and range of input–output options to simplify integration with other equipment (A320i printer, Domino North America).

Inserts increase

As FDA requires more information in medication guides and patient information, the size of package leaflets and outserts is increasing. One of the biggest measures 630 in.2 , but folds into a 1.25 1.25-in. square with 210 panels, which is substantially more than the previous maximum of 170 panels (leaflet–outsert, Mini Graphics). Printed materials also may include 3-D graphics that rely on the same software used for 3-D imagery in video games and 3-D movies to create accurate color, texture, and size (3D Label Graphics, Mini Graphics).

It's possible to fold an insert to a size even smaller than 1.25 1.25 in. At 1.125-in.2 , the insert can be applied automatically and consist of approximately 200 panels (Glued Capsert, Arthur Press).

If one sheet isn't big enough, two or more inserts can be stacked together. One piggybacked concept compatible with automatic application features two 1.25-in.2 inserts with as many as 170 panels each (multiserts, Cortegra and Chesapeake Pharmaceutical and Healthcare Packaging; multipack bundles, The Challenge Printing).

Hallie Forcinio is Pharmaceutical Technology's Packaging Forum editor, 4708 Morningside Drive, Cleveland, OH 44109, tel. 216.351.5824, fax 216.351.5684,


blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
| Weekly

What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Jim Miller Outsourcing Outlook Jim MillerOutside Looking In
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAdvances in Large-Scale Heterocyclic Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler New Era for Generic Drugs
Sean Milmo European Regulatory WatchSean MilmoTackling Drug Shortages
New Congress to Tackle Health Reform, Biomedical Innovation, Tax Policy
Combination Products Challenge Biopharma Manufacturers
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality
Source: Pharmaceutical Technology,
Click here